International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

Michael Charlton, Josh Levitsky, Bashar Aqel, John O'Grady, Julie Hemibach, Mary Rinella, John Fung, Marwan Ghabril, Ray Thomason, Patrizia Burra, Ester Coelho Little, Marina Berenguer, Abraham Shaked, James Trotter, John Roberts, Manuel Rodriguez-Davalos, Mohamed Rela, Elizabeth Pomfret, Caroline Heyrend, Juan Gallegos-OrozcoFaouzi Saliba

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.

Original languageEnglish (US)
Pages (from-to)727-743
Number of pages17
Issue number5
StatePublished - May 1 2018

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients'. Together they form a unique fingerprint.

Cite this